Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Cancer Immunology, Immunotherapy : CII|May 22, 2022
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patientsKentaro Jingushi, Atsunari Kawashima, Takuro Saito, et al.
Cancer Science|March 15, 2021
Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkersEisuke Tomiyama, Kyosuke Matsuzaki, Kazutoshi Fujita, et al.
Anticancer Research|January 31, 2025
Efficacy of Second-line Nivolumab <i>Versus</i> Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone MetastasesGaku Yamamichi, Taigo Kato, Akihiro Yoshimura, et al.
International Journal of Clinical Oncology|February 7, 2025
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testingShin Kobayashi, Yoshiaki Nakamura, Tadayoshi Hashimoto, et al.
Cancer Science|November 20, 2024
Bacterial information in serum extracellular vesicles reflects the inflammation of adherent perinephric fatToshihiro Uemura, Atsunari Kawashima, Kentaro Jingushi, et al.
Cancer Science|March 20, 2019
Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinomaYujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.
Japanese Journal of Clinical Oncology|February 2, 2024
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC studyAkira Nagahara, Motohide Uemura, Mototaka Sato, et al.
International Journal of Clinical Oncology|July 13, 2022
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective studyTaigo Kato, Kazutoshi Fujita, Takafumi Minami, et al.
Anticancer Research|February 27, 2026
SLFN11 Drives GM-CSF-mediated M1 Macrophage Polarization and Enhances Immunotherapy Response in Renal Cell CarcinomaYohei Okuda, Junko Murai, Tsuyoshi Takashima, et al.
Cancer Science|December 12, 2018
Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinomaYoshiyuki Yamamoto, Motohide Uemura, Masashi Fujita, et al.
Pageof 18